Digoxin tablets--a review of the bioavailability problems.
A review is presented of the more significant aspects of recent bioavailability studies on digoxin tablets that have led to the identification of variations among commercially available tablets and of the correlation of the methods commonly used in such bioavailability evaluations. Pharmacopeial requirements for tablet-to-tablet uniformity of content do not automatically yield uniformity of bioavailability. In vitro dissolution rate of digoxin tablets generally has been shown to correlate with in vivo bioavailability, and this has led to new governmental and pharmacopeial requirements for digoxin tablets. However, some recent reports have shown that in vitro dissolution rate may not always correlate well with bioavailability. The relevance and significance of digoxin tablet bioavailability to clinical effects and therapeutics are briefly discussed.
D001682:Biological Availability; D004077:Digoxin / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D012995:Solubility; D013607:Tablets / Q000592:standards
D013607:Tablets; D004077:Digoxin